Get started
Ensysce Biosciences, Inc.Ensysce Biosciences, Inc.Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

ENSC chart


Full chart

ENSC upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪7.79 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.7559 USD
Net income (FY)
‪−10.61 M‬ USD
Revenue (FY)
‪2.23 M‬ USD
Shares float
‪14.62 M‬
Beta (1Y)
−1.29

Employees


Employees (FY)
9
Change (1Y)
−3 −25.00%
Revenue / Employee (1Y)
‪247.84 K‬ USD
Net income / Employee (1Y)
‪−1.18 M‬ USD

About Ensysce Biosciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
D. Lynn Kirkpatrick
Website
ensysce.com
Headquarters
La Jolla
Founded
2003
FIGI
BBG00JFF4174
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ENSC news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ENSC is 0.7787 USD — it has increased by 5.42% in the past 24 hours. Watch Ensysce Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ensysce Biosciences, Inc. stocks are traded under the ticker ENSC.
ENSC stock has risen by 7.44% compared to the previous week, the month change is a 139.26% rise, over the last year Ensysce Biosciences, Inc. has showed a −18.68% decrease.
We've gathered analysts' opinions on Ensysce Biosciences, Inc. future price: according to them, ENSC price has a max estimate of 8.60 USD and a min estimate of 8.60 USD. Watch ENSC chart and read a more detailed Ensysce Biosciences, Inc. stock forecast: see what analysts think of Ensysce Biosciences, Inc. and suggest that you do with its stocks.
ENSC reached its all-time high on Feb 1, 2021 with the price of 5,757.6000 USD, and its all-time low was 0.1412 USD and was reached on Oct 15, 2024. View more price dynamics on ENSC chart.
See other stocks reaching their highest and lowest prices.
ENSC stock is 64.80% volatile and has beta coefficient of −1.29. Track Ensysce Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ensysce Biosciences, Inc. there?
Today Ensysce Biosciences, Inc. has the market capitalization of ‪8.21 M‬, it has increased by 62.80% over the last week.
Yes, you can track Ensysce Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Ensysce Biosciences, Inc. is going to release the next earnings report on Nov 11, 2024. Keep track of upcoming events with our Earnings Calendar.
ENSC earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.39 USD resulting in a 43.59% surprise. The estimated earnings for the next quarter are −0.17 USD per share. See more details about Ensysce Biosciences, Inc. earnings.
Ensysce Biosciences, Inc. revenue for the last quarter amounts to ‪200.00 K‬ USD, despite the estimated figure of ‪300.00 K‬ USD. In the next quarter, revenue is expected to reach ‪200.00 K‬ USD.
ENSC net income for the last quarter is ‪−1.97 M‬ USD, while the quarter before that showed ‪−3.12 M‬ USD of net income which accounts for 36.86% change. Track more Ensysce Biosciences, Inc. financial stats to get the full picture.
No, ENSC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 7, 2024, the company has 9.00 employees. See our rating of the largest employees — is Ensysce Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ensysce Biosciences, Inc. EBITDA is ‪−9.66 M‬ USD, and current EBITDA margin is −480.52%. See more stats in Ensysce Biosciences, Inc. financial statements.
Like other stocks, ENSC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ensysce Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ensysce Biosciences, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ensysce Biosciences, Inc. stock shows the sell signal. See more of Ensysce Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.